Skip to Content

Hyrimoz Approval History

FDA Approved: Yes (First approved October 30, 2018)
Brand name: Hyrimoz
Generic name: adalimumab-adaz
Dosage form: Injection
Company: Sandoz Inc.
Treatment for: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Maintenance, Ulcerative Colitis, Plaque Psoriasis

Hyrimoz (adalimumab-adaz) is an anti-TNF-α monoclonal antibody biosimilar to Humira, approved for the treatment of various inflammatory diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Development History and FDA Approval Process for Hyrimoz

DateArticle
Oct 31, 2018Approval FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide